https://allsci.com/news/regulatory-pathways/china-cell-gene-therapy-pioneer-program/ AllScien 2026-08-20T15:56:34.465677Z China's CDE launches PIONEER Program for cell and gene therapy products https://allsci.com/news/licensing-and-partnerships/rsv-antibody-greater-china-simcere-secures/ AllScien 2026-08-20T15:50:51.239482Z Simcere takes on Beyfortus with China rights deal for long-acting RSV antibody https://allsci.com/news/funding/amylyx-avexitide-funding-triples-fundraising/ AllScien 2026-08-20T15:26:59.550084Z Amylyx ups fundraising target to USD 500m after avexitide's Phase III win in hypoglycemia https://allsci.com/news/licensing-and-partnerships/lupin-yuvezzi-presbyopia-expands-footprint-with/ AllScien 2026-08-20T15:25:10.573815Z Lupin expands presbyopia footprint with EUR 75m Yuvezzi licensing deal across Europe https://allsci.com/news/regulatory/fda-fast-track-lti-03-ipf-grants-designation-to/ AllScien 2026-08-20T15:06:46.197743Z FDA grants Fast Track Designation to Rein's LTI-03 for idiopathic pulmonary fibrosis https://allsci.com/news/regulatory/safusidenib-idh1-mutant-glioma-fda-grants/ AllScien 2026-08-20T14:56:52.038669Z FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma https://allsci.com/news/licensing-and-partnerships/urogen-intragel-collaboration-expands-beyond/ AllScien 2026-08-20T14:47:24.332845Z UroGen takes first step beyond urothelial cancer with IntraGel deal https://allsci.com/news/approvals/licancopan-pnh-approval-china-hengruis-becomes/ AllScien 2026-08-20T14:42:04.631756Z Hengrui's licancopan wins China PNH approval after outperforming eculizumab in Phase III https://allsci.com/news/first-in-human-trials/nlrp3-inhibitor-brain-ac-immunes-reaches-with/ AllScien 2026-08-20T14:24:49.488792Z AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study https://allsci.com/news/research/car-t-cell-synthetic-transcription-factors/ AllScien 2026-08-20T13:02:39.182487Z Stanford-led team engineers synthetic transcription factors to boost CAR-T cells https://allsci.com/news/research/sting-mrna-vaccine-delayed-activation-lnp-mrna/ AllScien 2026-08-20T12:51:23.303036Z Peking University team develops delayed STING activation strategy for mRNA cancer vaccines https://allsci.com/news/licensing-and-partnerships/amgen-tscan-termination-terminates-collaboration/ AllScien 2026-08-20T12:34:43.179318Z Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones https://allsci.com/news/venture-financing/kynexis-series-a-funding-schizophrenia-raises-eur/ AllScien 2026-08-20T12:27:59.317505Z Kynexis takes Series A to EUR 97 million as Novartis backs schizophrenia cognition drug https://allsci.com/news/regulatory-pathways/fda-immunotherapy-potency-guidance-fdacber-issues/ AllScien 2026-08-20T12:08:17.273876Z FDA sets out potency testing approach for personalized cancer vaccines https://allsci.com/news/regulatory-pathways/fda-gene-therapy-guidance-issues-on-cellular-and/ AllScien 2026-08-20T11:55:20.029793Z FDA consolidates cell and gene therapy development guidance https://allsci.com/news/research/ai-antibody-design-specifica-led-benchmark-finds/ AllScien 2026-08-20T11:50:09.583467Z AI antibody design struggles to beat simple baselines in 29-organization benchmark https://allsci.com/news/licensing-and-partnerships/kio-301-south-korea-licensing-kiora-completes/ AllScien 2026-08-20T09:49:52.231993Z Kiora completes global licensing map for KIO-301 with South Korea deal to Chong Kun Dang https://allsci.com/news/approvals/pasatru-fda-approval-fop-regenerons-wins-second/ AllScien 2026-08-20T09:47:05.128855Z FDA approves Regeneron’s Pasatru as second therapy for rare bone disease FOP https://allsci.com/news/regulatory/ecopipam-tourette-syndrome-fda-approval/ AllScien 2026-08-20T09:33:26.578633Z Teva's first-in-class Tourette drug filed for approval with FDA priority status https://allsci.com/news/licensing-and-partnerships/rna-vaccines-lilly-bets-on-next-generation-with/ AllScien 2026-08-20T09:28:43.301794Z Lilly expands vaccine push with Amplitude's next-generation RNA platform https://allsci.com/news/approvals/genglycos-gene-therapy-gsd-fda-approves-as-first/ AllScien 2026-08-20T09:23:42.976568Z FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia https://allsci.com/news/licensing-and-partnerships/lbl-051-license-deal-oblenio-converts-option-to/ AllScien 2026-08-20T09:19:06.602444Z Oblenio exercises LBL-051 option, securing worldwide rights from Leads Biolabs https://allsci.com/news/clinical-trials/pancreatic-cancer-phase-ii-trial-genfleet/ AllScien 2026-08-20T09:12:06.000256Z GenFleet tests dual RAS blockade, cachexia strategy in Phase II pancreatic cancer trial https://allsci.com/news/clinical-trials/opamtistomig-nsclc-phase-ii-leads-biolabs/ AllScien 2026-08-20T09:04:05.133247Z Leads Biolabs' PD-L1/4-1BB opamtistomig posts 77.4% ORR in 1st-line sqNSCLC https://allsci.com/news/licensing-and-partnerships/lag-3-inhibitor-program-onco-innovations-secures/ AllScien 2026-08-20T08:56:37.316815Z Onco-Innovations secures option on LAG-3 small-molecule program from Ifowonco https://allsci.com/news/funding/edesa-biotech-funding-vitiligo-raises-usd-25m-to/ AllScien 2026-08-20T08:15:37.577434Z Edesa Biotech raises USD 25m to fuel vitiligo Phase II https://allsci.com/news/licensing-and-partnerships/lutetium-177-radiopharmaceutical-akiram-secures/ AllScien 2026-08-20T07:55:24.423711Z Akiram secures lutetium-177 supply deal for CD44v6 radiopharmaceutical https://allsci.com/news/venture-financing/ai-disease-models-patient-data-network-bio/ AllScien 2026-08-19T15:19:13.007481Z Network Bio raises USD 50m for patient tissue-trained AI platform https://allsci.com/news/licensing-and-partnerships/klotho-ind-filing-jocasta-eliminates-ip-risk/ AllScien 2026-08-19T15:16:40.815903Z Jocasta cuts Unity from α-klotho IP chain with direct UCSF deal https://allsci.com/news/first-in-human-trials/crispr-treg-therapy-cancer-coregens-crispr-edited/ AllScien 2026-08-19T15:03:37.633033Z CoRegen takes CRISPR-edited Tregs into first human cancer trial https://allsci.com/news/venture-financing/oncolytic-immunotherapy-funding-kalivir-raises/ AllScien 2026-08-19T14:58:39.701241Z KaliVir raises USD 14m as oncolytic virus clears first IV cohort https://allsci.com/news/licensing-and-partnerships/il-7-therapy-clinical-development-tolerance-bio/ AllScien 2026-08-19T14:17:46.800790Z Tolerance Bio licenses clinical-stage IL-7 therapy to enter thymic function studies https://allsci.com/news/clinical-trials/enhertu-her2-lung-cancer-becomes-first/ AllScien 2026-08-19T13:55:10.390198Z Enhertu becomes first HER2-directed therapy to beat chemoimmunotherapy in 1st-line lung cancer https://allsci.com/news/clinical-trials/regn7041-uveitis-trial-regeneron-terminates-phase/ AllScien 2026-08-19T13:49:30.328923Z Regeneron halts first-in-human REGN7041 trial after safety event https://allsci.com/news/clinical-trials/prmt5-inhibitor-pancreatic-cancer-ideaya-partners/ AllScien 2026-08-19T13:19:41.676716Z Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo https://allsci.com/news/licensing-and-partnerships/bioarctic-glioblastoma-collaboration-expands/ AllScien 2026-08-19T13:09:56.473165Z BioArctic expands BrainTransporter platform from neurodegeneration to glioblastoma with Mesenkia collaboration https://allsci.com/news/clinical-trials/pfizer-iga-nephropathy-trial-termination/ AllScien 2026-08-19T12:44:32.996437Z Pfizer drops IgAN candidate PF-07985631 over benefit-risk assessment https://allsci.com/news/clinical-trials/evogliptin-aortic-stenosis-trial-rednvia/ AllScien 2026-08-19T12:29:18.867558Z REDNVIA terminates Phase II/III trial of DPP-4 inhibitor evogliptin in aortic stenosis https://allsci.com/news/clinical-trials/neoantigen-therapy-melanoma-merck-and-modernas/ AllScien 2026-08-19T12:08:14.955167Z Merck, Moderna neoantigen therapy delivers landmark Phase III melanoma win https://allsci.com/news/research/senolytic-drug-mycobacterial-infection-senescent/ AllScien 2026-08-19T12:04:38.302544Z University of Milan team turns senolytic drug against hard-to-treat mycobacterial infection https://allsci.com/news/grants/type-1-diabetes-biomarkers-battelle-pacific/ AllScien 2026-08-19T08:51:11.081574Z NIH funds new blood biomarkers to track islet dysfunction in type 1 diabetes https://allsci.com/news/grants/oral-influenza-antiviral-stanford-secures-127m/ AllScien 2026-08-19T08:45:28.426804Z Stanford moving novel oral influenza antiviral toward IND with NIAID backing https://allsci.com/news/licensing-and-partnerships/eli-lilly-alzheimers-gsm-completes-usd-10-million/ AllScien 2026-08-19T08:41:59.751117Z Lilly completes USD 10m payment for preclinical Alzheimer's GSM from AlzeCure https://allsci.com/news/regulatory/pelareorep-colorectal-cancer-fda-aligns-with/ AllScien 2026-08-19T08:38:40.670386Z Oncolytics gains FDA alignment on pivotal path for pelareorep in colorectal cancer https://allsci.com/news/regulatory/parg-inhibitor-breast-cancer-858-therapeutics/ AllScien 2026-08-19T08:34:45.703514Z 858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer https://allsci.com/news/policy/fda-generative-ai-medical-devices-seeks-public/ AllScien 2026-08-19T08:32:33.861243Z FDA seeks input on regulatory framework for generative AI-enabled medical devices https://allsci.com/news/funding/avexitide-funding-phase-iii-amylyx-raises-usd/ AllScien 2026-08-19T08:28:49.525119Z Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win https://allsci.com/news/licensing-and-partnerships/gsk-dengue-antibody-license-secures-exclusive/ AllScien 2026-08-19T08:13:42.286884Z GSK secures preclinical dengue antibody from Chugai